tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Teladoc (TDOC) and Guardant Health (GH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Exact Sciences (EXASResearch Report), Teladoc (TDOCResearch Report) and Guardant Health (GHResearch Report).

Exact Sciences (EXAS)

BTIG analyst Mark Massaro reiterated a Buy rating on Exact Sciences yesterday and set a price target of $100.00. The company’s shares closed last Wednesday at $62.52, close to its 52-week low of $56.77.

According to TipRanks.com, Massaro is a 4-star analyst with an average return of 5.8% and a 46.3% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Ginkgo Bioworks Holdings, Accelerate Diagnostics, and Lucid Diagnostics.

Currently, the analyst consensus on Exact Sciences is a Strong Buy with an average price target of $90.50, which is a 48.0% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $95.00 price target.

See the top stocks recommended by analysts >>

Teladoc (TDOC)

In a report released yesterday, David Larsen from BTIG maintained a Hold rating on Teladoc. The company’s shares closed last Wednesday at $55.99, close to its 52-week low of $50.08.

According to TipRanks.com, Larsen is ranked 0 out of 5 stars with an average return of -9.5% and a 31.5% success rate. Larsen covers the Technology sector, focusing on stocks such as Health Catalyst, American Well, and Sharecare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $98.00 average price target, a 71.2% upside from current levels. In a report issued on April 19, Deutsche Bank also maintained a Hold rating on the stock with a $78.00 price target.

Guardant Health (GH)

In a report released yesterday, Sung Ji Nam from BTIG initiated coverage with a Buy rating on Guardant Health and a price target of $115.00. The company’s shares closed last Wednesday at $64.69, close to its 52-week low of $46.87.

According to TipRanks.com, Nam is a 2-star analyst with an average return of 0.1% and a 48.7% success rate. Nam covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Standard BioTools, and Genetron Holdings.

Guardant Health has an analyst consensus of Strong Buy, with a price target consensus of $120.78.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EXAS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed